Vahabi Surena, Torshabi Maryam, Esmaeil Nejad Azadeh
Department of Periodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Dental Biomaterials, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Mater Sci Mater Med. 2016 Dec;27(12):182. doi: 10.1007/s10856-016-5802-6. Epub 2016 Oct 27.
Predictable regeneration of alveolar bone defects has always been a challenge in implant dentistry. Bone allografts are widely used bone substitutes with controversial osteoinductive activity. This in vitro study aimed to assess the osteogenic potential of some commercially available freeze-dried bone allografts supplemented with human recombinant platelet-derived growth factor-BB and transforming growth factor beta-1. Cell viability, mineralization, and osteogenic gene expression of MG-63 osteoblast-like cells were compared among the allograft alone, allograft/platelet-derived growth factor-BB, allograft/transforming growth factor beta-1, and allograft/platelet-derived growth factor-BB/transforming growth factor beta-1 groups. The methyl thiazol tetrazolium assay, real-time quantitative reverse transcription polymerase chain reaction and alizarin red staining were performed, respectively, for assessment of cell viability, differentiation, and mineralization at 24-72 h post treatment. The allograft with greater cytotoxic effect on MG-63 cells caused the lowest differentiation among the groups. In comparison with allograft alone, allograft/transforming growth factor beta-1, and allograft/transforming growth factor beta-1/platelet-derived growth factor-BB caused significant upregulation of bone sialoprotein and osteocalcin osteogenic mid-late marker genes, and resulted in significantly higher amounts of calcified nodules especially in mineralized non-cytotoxic allograft group. Supplementation of platelet-derived growth factor-BB alone in 5 ng/mL concentration had no significant effect on differentiation or mineralization markers. According to the results, transforming growth factor beta-1 acts synergistically with bone allografts to enhance the osteogenic differentiation potential. Therefore, this combination may be useful for rapid transformation of undifferentiated cells into bone-forming cells for bone regeneration. However, platelet-derived growth factor-BB supplementation did not support this synergistic ability to enhance osteogenic differentiation and thus, further investigations are required.
在种植牙科领域,可预测的牙槽骨缺损再生一直是一项挑战。骨同种异体移植物是广泛使用的骨替代物,但其骨诱导活性存在争议。本体外研究旨在评估一些市售的冻干骨同种异体移植物在补充人重组血小板衍生生长因子 -BB 和转化生长因子β -1 后的成骨潜力。比较了单独同种异体移植物、同种异体移植物/血小板衍生生长因子 -BB、同种异体移植物/转化生长因子β -1 以及同种异体移植物/血小板衍生生长因子 -BB/转化生长因子β -1 组中 MG-63 成骨样细胞的细胞活力、矿化和骨生成基因表达。分别进行了甲基噻唑四氮唑法、实时定量逆转录聚合酶链反应和茜素红染色,以评估处理后 24 - 72 小时的细胞活力、分化和矿化情况。对 MG-63 细胞具有更大细胞毒性作用的同种异体移植物在各组中导致的分化最低。与单独同种异体移植物相比,同种异体移植物/转化生长因子β -1 以及同种异体移植物/转化生长因子β -1/血小板衍生生长因子 -BB 导致骨唾液蛋白和骨钙素等骨生成中晚期标志物基因显著上调,并导致钙化结节数量显著增加,尤其是在矿化无细胞毒性的同种异体移植物组中。单独补充浓度为 5 ng/mL 的血小板衍生生长因子 -BB 对分化或矿化标志物没有显著影响。根据结果,转化生长因子β -1 与骨同种异体移植物协同作用以增强成骨分化潜力。因此,这种组合可能有助于将未分化细胞快速转化为成骨细胞以促进骨再生。然而,补充血小板衍生生长因子 -BB 并未支持这种增强成骨分化的协同能力,因此需要进一步研究。